Phase 1/2 Study of DSP-7888 in Patients With Myelodysplastic Syndrome (MDS)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Adegramotide/nelatimotide (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 20 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
- 20 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History